• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

“Game-Changer” Drug Is First New Asthma Attack Treatment In 50 Years

December 3, 2024 by Deborah Bloomfield

For the first time in half a century, scientists have hit on a new treatment for asthma attacks. Clinical trial results have shown that a drug called benralizumab is effective at treating acute attacks of both asthma and chronic obstructive pulmonary disease (COPD), and it works better than the current standard steroid treatment.

Asthma is thought to affect more than 262 million people worldwide, based on data from the 2019 Global Burden of Disease Study. Its symptoms include coughing, wheezing, and shortness of breath, which can worsen when people are exposed to certain triggers such as environmental allergens.

Advertisement

For COPD, it’s been tricky to pin down exactly how common it is, but it’s thought to be the third leading cause of death globally. Symptoms can be similar to those of asthma at first, but will typically get worse over time. This disease most often occurs in over-50s, and the main cause is smoking, as well as exposure to air pollution.

Sudden, acute symptom episodes of either disease can be fatal. About 50 percent of asthma attacks and 30 percent of COPD flare-ups are caused by inflammation resulting from large quantities of a type of white blood cell called eosinophils. These are called eosinophilic exacerbations, and risk causing permanent lung damage.

Despite the prevalence of these conditions, treatment for asthma has remained pretty much the same for the last 50 years. Steroid drugs like prednisolone are usually prescribed to try and control the inflammation in the lungs and reduce the chances of an attack, but they can have serious side effects and are not effective for all patients.

New options are needed – which is why the recent clinical trial of the drug benralizumab is so welcome. Led by scientists at King’s College London, the trial was conducted at hospitals in London and Oxford, UK.

Advertisement

The monoclonal antibody, which is given as an injection, is already in use to help manage some of the most severe asthma cases, but using it specifically to help asthma attacks was a new idea.

A cohort of 158 participants identified as being at high risk of an asthma attack or COPD flare-up were divided into three groups: the first received benralizumab injections and a placebo pill; the second received a placebo injection and the current standard prednisolone pills for five days; the third received both the new benralizumab injection and the standard steroid pills.

After 28 days, symptoms like coughing and breathlessness had significantly improved in those receiving benralizumab (with or without steroids). At 90 days, 74 percent of those only receiving the current standard treatment had needed further medical care. By contrast, those taking benralizumab needed fewer visits to the doctor or hospital and reported improved quality of life.

One of the patients who took part in the study was 77-year-old Geoffrey Pointing, who said in a statement, “Honestly, when you’re having a flare up, it’s very difficult to tell anybody how you feel – you can hardly breathe. Anything that takes that away and gives you back a normal life is what you want. But on the injections, it’s fantastic.”

Advertisement

“The big advance […] is the finding that targeted therapy works in asthma and COPD attacks,” said lead investigator Professor Mona Bafadhel. “Instead of giving everyone the same treatment, we found targeting the highest risk patients with very targeted treatment, with the right level of inflammation was much better than guessing what treatment they needed.”

“This could be a game-changer for people with asthma and COPD. Treatment for asthma and COPD exacerbations have not changed in 50 years despite causing 3.8 million deaths worldwide a year combined.”

The study is published in The Lancet Respiratory Medicine.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Cricket-Manchester test likely to be postponed after India COVID-19 case
  2. EU to attend U.S. trade meeting put in doubt by French anger
  3. Soccer-West Ham win again, Leicester and Napoli falter
  4. Lacking Company, A Dolphin In The Baltic Is Talking To Himself

Source Link: “Game-Changer” Drug Is First New Asthma Attack Treatment In 50 Years

Filed Under: News

Primary Sidebar

  • Armadillo Girdled Lizards Turn Themselves Into An Ouroboros To Protect Their Underbelly
  • Opium Found In Rare Ancient Egyptian Vase Dedicated To “Great King” Xerxes
  • COVID-19 mRNA Vaccines Boosted Survival Almost 5-Fold In Some Cancer Patients
  • Sleuths Uncover Hidden Message In CIA’s Mysterious Kryptos Sculpture After 35 Years
  • Meat-Eating In US Cities Emits 329 Million Tons Of Carbon – But This Could Be Cut In Half
  • The World’s Oldest Known Chimpanzee Is Over 80 Years Old, And He’s Our Favorite Chill Childminder
  • Mysterious JWST Object “Capotauro” Might Be The First Galaxy In The Universe
  • 4.4-Million-Year-Old Ankle Bone Suggests Humans Evolved From African Ape-Like Ancestor
  • Hib: The Deadliest Disease You Might Never Have Heard Of (Because Vaccines Are Awesome)
  • The Legend Of Ol’ Rip The Horned Toad Who Reportedly Survived 31 Years Of Hibernation And Met President Coolidge
  • Newly Discovered “Reset Button” Lets Mathematicians Undo Any Rotation
  • Bear-Sized Snow Sloths? Meet Megalonyx, The Ice Age Giants That Lived Until 13,000 Years Ago
  • Why Can’t Mormons Drink Coffee?
  • In 1997, A Zoo Chimp Amazed Scientists By Gathering Rocks To Throw At Visitors
  • YouTuber Films Laser Light At 2 Billion Frames Per Second In His Garage
  • The Time To Watch Comet Lemmon Is Now
  • Ig Nobel-Winning “Butt-Breathing” Technique Moves One Step Closer To Saving Lives
  • What Is The Oldest Religion In The World?
  • This Mini Dragon Is One Of The World’s Rarest Amphibians With Just 150 Individuals Living In One Lake
  • “Alien Mothership” Hypothesis About To Have Key Test As Interstellar Object 3I/ATLAS Hits Solar Conjunction And Perihelion
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version